Press release
Cervical Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Regeneron Pharma, Akesobio, AstraZeneca, Genexine, Inc., Merck KGaA
"Cervical Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cervical Cancer Market.
The Cervical Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cervical Cancer Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Cervical Cancer treatment therapies with a considerable amount of success over the years.
*
Cervical Cancer companies working in the treatment market are Rubius Therapeutics, Nurix, PDS Biotechnology Corporation, Vaccibody AS, Roche, EMD Serono, Eli Lilly and Company, AkesoBiopharma, Regeneron Pharmaceuticals, and others, are developing therapies for the Cervical Cancer treatment
*
Emerging Cervical Cancer therapies such as - RTX 321, DeTIL 0255, PDS 0101, VB10.16, Tiragolumab, Bintrafusp alfa, Gemcitabine, Cadonilimab, Cemiplimab, and others are expected to have a significant impact on the Cervical Cancer market in the coming years.
*
In July 2025, Tisotumab vedotin (Tivdak), an innovative antibody-drug conjugate (ADC), marks a notable advancement in the treatment of recurrent cervical cancer. This tissue factor-targeting therapy signifies a shift in the current treatment landscape, offering better outcomes in progression-free and overall survival compared to traditional chemotherapy. The study reported an increase in response rates from 5% to 17%. However, experts note that while these results are encouraging, the survival benefits-1.5 months in progression-free survival and 2 months in overall survival-remain modest, underscoring the need for continued progress in cervical cancer treatment.
*
In March 2025, According to results from the second interim analysis of the Phase 3 KEYNOTE-A18 trial (NCT04221945), presented at the 2025 SGO Annual Meeting on Women's Cancer, the combination of pembrolizumab (Keytruda) with chemoradiotherapy, followed by pembrolizumab alone, significantly and/or meaningfully improved overall survival (OS) and time to second disease progression or death (PFS2). It also demonstrated a sustained progression-free survival (PFS) advantage compared to chemoradiotherapy alone in patients with newly diagnosed, high-risk, stage IB2 to IIB, node-positive, or stage III to IVA locally advanced cervical cancer.
*
In May 2025, The FDA awarded fast track designation to ADRX-0706, a Nectin-4-targeting antibody-drug conjugate (ADC), for treating advanced cervical cancer. This designation aims to speed up the development and review of treatments that fulfill urgent medical needs for serious diseases.
*
In December 2024, The FDA granted fast track designation to CRB-701, a Nectin-4-targeting antibody-drug conjugate (ADC), for the potential treatment of adults with relapsed/refractory metastatic cervical cancer. CRB-701 is a next-generation ADC that incorporates a site-specific, cleavable linker, a uniform drug-to-antibody ratio of 2, and a novel monoclonal antibody targeting Nectin-4. It was designed to overcome the dose-limiting toxicities associated with the linker-payload system used in enfortumab vedotin-efjv (Padcev).
*
In March 2024, Merck (MSD) has announced that the Phase III KEYNOTE-A18 (ENGOT-cx11/GOG-3047) clinical trial of Keytruda combined with chemoradiotherapy (CRT) in cervical cancer patients has achieved its primary endpoint. This double-blind, randomized trial is being conducted by MSD in collaboration with the European Network for Gynecological Oncology Trial (ENGOT) groups and the GOG Foundation.
Cervical Cancer Overview
Cervical cancer is a type of cancer that develops in the lower part of the uterus, known as the cervix. It usually begins with abnormal cell changes that grow uncontrollably and can spread to nearby tissues if not treated early.
Get a Free Sample PDF Report to know more about Cervical Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Cervical Cancer Drugs Under Different Phases of Clinical Development Include:
*
RTX 321: Rubius Therapeutics
*
DeTIL 0255: Nurix
*
PDS 0101: PDS Biotechnology Corporation
*
VB10.16: Vaccibody AS
*
Axalimogene filolisbac: Advaxis
*
Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
*
Tiragolumab: Roche
*
AK104: Akeso
*
Bintrafusp alfa: EMD Serono
*
Durvalumab: AstraZeneca
*
Gemcitabine: Eli Lilly and Company
*
HLX10: Shanghai Henlius Biotech
*
Cadonilimab: AkesoBiopharma
*
Cemiplimab: Regeneron Pharmaceuticals
Route of Administration
Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Inhalation
*
Inhalation/Intravenous/Oral
*
Intranasal
*
Intravenous
*
Intravenous/ Subcutaneous
*
NA
*
Oral
*
Oral/intranasal/subcutaneous
*
Parenteral
*
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
*
Antibody
*
Antisense oligonucleotides
*
Immunotherapy
*
Monoclonal antibody
*
Peptides
*
Protein
*
Recombinant protein
*
Small molecule
*
Stem Cell
*
Vaccine
Cervical Cancer Pipeline Therapeutics Assessment
*
Cervical Cancer Assessment by Product Type
*
Cervical Cancer By Stage and Product Type
*
Cervical Cancer Assessment by Route of Administration
*
Cervical Cancer By Stage and Route of Administration
*
Cervical Cancer Assessment by Molecule Type
*
Cervical Cancer by Stage and Molecule Type
DelveInsight's Cervical Cancer Report covers around 70+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Cervical Cancer product details are provided in the report. Download the Cervical Cancer pipeline report to learn more about the emerging Cervical Cancer therapies [https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Cervical Cancer Therapeutics Market include:
Key companies developing therapies for Cervical Cancer are - Regeneron Pharmaceuticals, Akesobio, AstraZeneca, Genexine, Inc., Merck KGaA, Seagen Inc., Vaccibody AS, Qilu Pharmaceutical Co., Ltd., Genor Biopharma Co., Ltd., Roche, Guangzhou Gloria Biosciences Co., Ltd., Lee's Pharmaceutical Limited, BeiGene, Henlix Biotech, Biocad, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Cellid Co., Ltd., Innovent Biologics, Zeria Pharmaceutical, Advaxis, Inc., Hookipa Biotech GmbH, GlaxoSmithKline, Iovance Biotherapeutics, Inc., NETRIS Pharma, Rubius Therapeutics, Repertoire Immune Medicines, SOTIO Biotech a.s., VM Oncology, LLC, Andes Biotechnologies, Transgene, Xencor, Inc., Exelixis, Ocellaris Pharma, Inc, Fate Therapeutics, Arcus Biosciences, In., MacroGenics, and others.
Cervical Cancer Pipeline Analysis:
The Cervical Cancer pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Cervical Cancer with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cervical Cancer Treatment.
*
Cervical Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Cervical Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cervical Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cervical Cancer drugs and therapies [https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Cervical Cancer Pipeline Market Drivers
*
Increase in the incidence of oncological disease, large number of ongoing clinical trials are some of the important factors that are fueling the Cervical Cancer Market.
Cervical Cancer Pipeline Market Barriers
*
However, high cost of therapy, side-effects associated and other factors are creating obstacles in the Cervical Cancer Market growth.
Scope of Cervical Cancer Pipeline Drug Insight
*
Coverage: Global
*
Key Cervical Cancer Companies: Rubius Therapeutics, Nurix, PDS Biotechnology Corporation, Vaccibody AS, Roche, EMD Serono, Eli Lilly and Company, AkesoBiopharma, Regeneron Pharmaceuticals, and others
*
Key Cervical Cancer Therapies: RTX 321, DeTIL 0255, PDS 0101, VB10.16, Tiragolumab, Bintrafusp alfa, Gemcitabine, Cadonilimab, Cemiplimab, and others
*
Cervical Cancer Therapeutic Assessment: Cervical Cancer current marketed and Cervical Cancer emerging therapies
*
Cervical Cancer Market Dynamics: Cervical Cancer market drivers and Cervical Cancer market barriers
Request for Sample PDF Report for Cervical Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
Cervical Cancer Report Introduction
2
Cervical Cancer Executive Summary
3
Cervical Cancer Overview
4
Cervical Cancer- Analytical Perspective In-depth Commercial Assessment
5
Cervical Cancer Pipeline Therapeutics
6
Cervical Cancer Late Stage Products (Phase II/III)
7
Cervical Cancer Mid Stage Products (Phase II)
8
Cervical Cancer Early Stage Products (Phase I)
9
Cervical Cancer Preclinical Stage Products
10
Cervical Cancer Therapeutics Assessment
11
Cervical Cancer Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Cervical Cancer Key Companies
14
Cervical Cancer Key Products
15
Cervical Cancer Unmet Needs
16
Cervical Cancer Market Drivers and Barriers
17
Cervical Cancer Future Perspectives and Conclusion
18
Cervical Cancer Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cervical-cancer-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-by-delveinsight-regeneron-pharma-akesobio-astrazeneca-genexine-inc-merck-kgaa]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cervical Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Regeneron Pharma, Akesobio, AstraZeneca, Genexine, Inc., Merck KGaA here
News-ID: 4133917 • Views: …
More Releases from ABNewswire
Schneider Electric Trains On Energy Management
Schneider Electric has surpassed its goal of training some one million people in energy management, a cornerstone of its commitment to inclusive energy transition and youth empowerment.
According to its Q2 2025 extra-financial results released at the weekend, a significant step as it enters the final stretch of its 2021-2025 Schneider Sustainability Impact (SSI) programme, it said the milestone, aligned with World Youth Skills Day 2025, is driven by the Youth…
Liver Cirrhosis Market Predicted to See Upsurge Through 2034, Highlights DelveIn …
DelveInsight's "Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Liver Cirrhosis, historical and forecasted epidemiology as well as the Liver Cirrhosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Liver Cirrhosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Cirrhosis Market Forecast [https://www.delveinsight.com/sample-request/liver-cirrhosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key…
Swoop's first fibre-to-the-premises network
Swoop Infrastructure launches its first fibre-to-the-premises network in WA, connecting 1,000 homes in Geraldton with ultra-fast speeds up to 8 Gbps-marking a major step in delivering future-ready broadband to regional Australia.
We're proud to announce a major milestone for Swoop Infrastructure (Swoop's wholesale network arm), the successful deployment of our first fibre-to-the-premises (FTTP) wholesale network in Western Australia.
This cutting-edge network connects 1,000 homes in Geraldton's Seacrest Estate [https://www.swoop.com.au/swoop-home-fibre/seacrest/] with ultra-fast broadband…
Turf Management Systems Grows Web Presence
Turf Management Systems (TMS), a Birmingham-based landscaping company specializing in comprehensive lawn and landscaping services, has announced a successful partnership with Webology, a veteran-operated digital marketing agency. The collaboration has resulted in a redesigned website that elevates TMS's online presence and enhances customer engagement through world-class content and functionality.
The three-month project delivered 25 new service pages, each tailored to highlight Turf Management Systems' offerings, including hardscaping, irrigation systems, and annual…
More Releases for Cervical
Increasing Cervical And Back Pain Prevalence Drives Demand For Cervical Pillows: …
"What market dynamics are playing a key role in accelerating the growth of the cervical pillows market?
The surge in incidence of cervical and back pain is predicted to boost the growth of the cervical pillows market. Such pains often afflict the neck and upper spine, resulting in discomfort and disturbed sleep. The increasing occurrence of these problems is linked to elements like a stationary lifestyle, amplified use of electronic gadgets,…
Cervical Cancer Screening Cervical Cancer Screening Market 2024 Global Share, Ke …
Global Cervical Cancer Screening Market 2024 Research report is segmented into several key regions, with production, consumption, revenue (million USD), market share and growth rate of Cervical Cancer Screening Industry in these regions, from 2024 to 2030 (forecast), covering North America, Europe, Asia Pacific, Middle East & Africa, South & Central America.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPBT00002661/?utm_source=OpenPR&utm_medium=10759
Key Players Analysis:
Abbott
Hologic Corporation
Qiagen N.V.
F Hoffmann-La Roche
Quest Diagnostics
BD
OncoHealth Corp.
Femasys, Inc.
TruScreen
Onko Solutions
The report covers key…
Cervical Cancer Vaccines Market – Insights
Combining the analysis capabilities and data integration with the relevant findings, the report has predicted the strong future growth of the Cervical Cancer Vaccines Market in all its geographical and product segments. The Cervical Cancer Vaccines market research gathers data about the customers, marketing strategy, competitors. The Cervical Cancer Vaccines The manufacturing industry is becoming increasingly dynamic and innovative, with more number of private players enrolling the industry.
Free Download PDF…
India Cervical Cancer Screening Market India Cervical Cancer Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Overview of the Cervical Cancer
1.1 Introduction
1.2 Stages of the Cervical Cancer
1.2.1 Stage 0
1.2.2 Stage 1
1.2.3 Stage 2
1.2.4 Stage 3
1.2.5 Stage 4
Occurrence Rate of the Cervical Cancer
2.1 Incidence of the Cervical Cancer in Indian States
…
Global Cervical Cancer Diagnostic Testing Devices Market 2017, Global Cervical C …
Focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer
Global Bronchoscopic Devices Market 2017, presents a professional and in-depth study on the current state of the Bronchoscopic Devices market globally, providing basic overview of Bronchoscopic Devices market including definitions, classifications, applications and industry chain structure, Bronchoscopic Devices Market report provides development policies and plans are discussed as well as manufacturing processes and cost…
North America Cervical Dysplasia Market grows with rising awareness about cervic …
Global Cervical Dysplasia Market: Snapshot
Cervical dysplasia is one of the fastest growing market in the field of cancer diagnosis and treatment. Cervical cancer is a precancerous stage and it can be completely cured by early detection. Rising consumer awareness in this regard has led to an increased demand for cervical screenings in the past few years. Government bodies in several developed countries conduct screening programs in order to improve…
